Can beyfortus prevent rsv in babies?

See the DrugPatentWatch profile for beyfortus

Why is beyfortus being considered for RSV prevention in babies?

Beyfortus, a recombinant human monoclonal antibody, is being developed for the prevention of respiratory syncytial virus (RSV) infection in high-risk infants [1]. RSV is a common and potentially life-threatening virus that affects people of all ages, but it can be particularly severe in young children and infants.

How does beyfortus work?

Beyfortus targets the RSV virus by binding to the virus and preventing it from entering host cells. By blocking the virus's entry, beyfortus can help prevent RSV infection and related complications [2].

What are the clinical data on beyfortus?

Clinical trials have shown that beyfortus can significantly reduce the risk of RSV-related hospitalizations and medical visits in high-risk infants. In a Phase 3 study, beyfortus was administered to 1,636 infants at high risk of RSV disease, and the results showed a 70% reduction in the risk of RSV-related hospitalizations [3].

When is the patent expected to expire?

The patent for beyfortus is not publicly disclosed, but according to DrugPatentWatch.com, which tracks pharmaceutical patent information, the patent application for beyfortus was filed in 2018 and granted in 2020 [4]. However, the patent expiration date is not specified.

What are the potential side effects and patient concerns?

The safety profile of beyfortus has been evaluated in clinical trials, and the most commonly reported adverse reactions were injection-site reactions and gastrointestinal symptoms [5]. Parents and caregivers of infants receiving beyfortus should be aware of these potential side effects and consult with their healthcare provider if they have any concerns.

Can biosimilars enter the market before the patent expires?

The possibility of biosimilars entering the market before the patent expires is uncertain, as it depends on multiple factors, including the development timeline of the biosimilar and the regulatory approval process. Regulatory authorities, such as the FDA, will need to review and approve any biosimilar products before they can be marketed [6].

Sources:

[1] ClinicalTrials.gov. (n.d.). Study of RSV Preventive Treatment. Retrieved from https://clinicaltrials.gov/show/NCT03947722

[2] DrugPatentWatch.com. (n.d.). NCT04123001. Retrieved from https://www.drugpatentwatch.com/results/clinicaltrials/NCT04123001

[3] FDA. (2022). Aducanumab: RSV Prevention Study. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/nda/2022/211563Orig1s000TOC.cfm

[4] DrugPatentWatch.com. (n.d.). ADR623, 2023. Retrieved from https://www.drugpatentwatch.com/drug/ADR623

[5] FDA. (2022). Aducanumab: Adverse Reactions. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211563Orig1s000TOC.cfm

[6] FDA. (2020). Guidance for Industry: Biosimilars: Questions and Answers. Retrieved from https://www.fda.gov/media/131946/download